Cargando…

Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry

BACKGROUND: Thrombocytopenia is associated with increased mortality in the general population, but few data exist in patients with atrial fibrillation (AF) taking oral anticoagulants. We investigated factor determinants of thrombocytopenia in a large cohort of patients affected by AF and its associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pastori, Daniele, Antonucci, Emilia, Violi, Francesco, Palareti, Gualtiero, Pignatelli, Pasquale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898797/
https://www.ncbi.nlm.nih.gov/pubmed/31656119
http://dx.doi.org/10.1161/JAHA.119.012596
_version_ 1783477027904421888
author Pastori, Daniele
Antonucci, Emilia
Violi, Francesco
Palareti, Gualtiero
Pignatelli, Pasquale
author_facet Pastori, Daniele
Antonucci, Emilia
Violi, Francesco
Palareti, Gualtiero
Pignatelli, Pasquale
author_sort Pastori, Daniele
collection PubMed
description BACKGROUND: Thrombocytopenia is associated with increased mortality in the general population, but few data exist in patients with atrial fibrillation (AF) taking oral anticoagulants. We investigated factor determinants of thrombocytopenia in a large cohort of patients affected by AF and its association with total mortality. METHODS AND RESULTS: Multicenter prospective cohort study, including 5215 patients with AF from the START (Survey on Anticoagulated Patients Register) registry, 3877 (74.3%) and 1338 (25.7%) on vitamin K or non–vitamin K antagonist oral anticoagulants, respectively. Thrombocytopenia was defined by a platelet count <150×10(9)/L. Determinants of thrombocytopenia were investigated, and all‐cause mortality was the primary survival end point of the study. Thrombocytopenia was present in 592 patients (11.4%). At multivariable logistic regression analysis, chronic kidney disease (odds ratio [OR], 1.257; P=0.030), active cancer (OR, 2.065; P=0.001), liver cirrhosis (OR, 7.635; P<0.001), and the use of diuretics (OR, 1.234; P=0.046) were positively associated with thrombocytopenia, whereas female sex (OR, 0.387; P<0.001) and the use of calcium channel blockers (OR, 0.787; P=0.032) were negatively associated. During a median follow‐up of 19.2 months (9942 patient‐years), 391 deaths occurred (rate, 3.93%/year). Mortality rate increased from 3.8%/year to 9.9%/year in patients with normal platelet count and in those with moderate‐severe thrombocytopenia, respectively (log‐rank test, P=0.009). The association between moderate‐severe thrombocytopenia and mortality persisted after adjustment for CHA (2) DS (2) VASc score (hazard ratio, 2.431; 95% CI, 1.254–4.713; P=0.009), but not in the fully adjusted multivariable Cox regression analysis model. CONCLUSIONS: Thrombocytopenia is common in patients with AF. Despite an increased incidence of mortality, thrombocytopenia was not associated with mortality at multivariable analysis. Thrombocytopenia may reflect the presence of comorbidities associated with poor survival in AF.
format Online
Article
Text
id pubmed-6898797
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68987972019-12-16 Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry Pastori, Daniele Antonucci, Emilia Violi, Francesco Palareti, Gualtiero Pignatelli, Pasquale J Am Heart Assoc Original Research BACKGROUND: Thrombocytopenia is associated with increased mortality in the general population, but few data exist in patients with atrial fibrillation (AF) taking oral anticoagulants. We investigated factor determinants of thrombocytopenia in a large cohort of patients affected by AF and its association with total mortality. METHODS AND RESULTS: Multicenter prospective cohort study, including 5215 patients with AF from the START (Survey on Anticoagulated Patients Register) registry, 3877 (74.3%) and 1338 (25.7%) on vitamin K or non–vitamin K antagonist oral anticoagulants, respectively. Thrombocytopenia was defined by a platelet count <150×10(9)/L. Determinants of thrombocytopenia were investigated, and all‐cause mortality was the primary survival end point of the study. Thrombocytopenia was present in 592 patients (11.4%). At multivariable logistic regression analysis, chronic kidney disease (odds ratio [OR], 1.257; P=0.030), active cancer (OR, 2.065; P=0.001), liver cirrhosis (OR, 7.635; P<0.001), and the use of diuretics (OR, 1.234; P=0.046) were positively associated with thrombocytopenia, whereas female sex (OR, 0.387; P<0.001) and the use of calcium channel blockers (OR, 0.787; P=0.032) were negatively associated. During a median follow‐up of 19.2 months (9942 patient‐years), 391 deaths occurred (rate, 3.93%/year). Mortality rate increased from 3.8%/year to 9.9%/year in patients with normal platelet count and in those with moderate‐severe thrombocytopenia, respectively (log‐rank test, P=0.009). The association between moderate‐severe thrombocytopenia and mortality persisted after adjustment for CHA (2) DS (2) VASc score (hazard ratio, 2.431; 95% CI, 1.254–4.713; P=0.009), but not in the fully adjusted multivariable Cox regression analysis model. CONCLUSIONS: Thrombocytopenia is common in patients with AF. Despite an increased incidence of mortality, thrombocytopenia was not associated with mortality at multivariable analysis. Thrombocytopenia may reflect the presence of comorbidities associated with poor survival in AF. John Wiley and Sons Inc. 2019-10-28 /pmc/articles/PMC6898797/ /pubmed/31656119 http://dx.doi.org/10.1161/JAHA.119.012596 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Pastori, Daniele
Antonucci, Emilia
Violi, Francesco
Palareti, Gualtiero
Pignatelli, Pasquale
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry
title Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry
title_full Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry
title_fullStr Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry
title_full_unstemmed Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry
title_short Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry
title_sort thrombocytopenia and mortality risk in patients with atrial fibrillation: an analysis from the start registry
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898797/
https://www.ncbi.nlm.nih.gov/pubmed/31656119
http://dx.doi.org/10.1161/JAHA.119.012596
work_keys_str_mv AT pastoridaniele thrombocytopeniaandmortalityriskinpatientswithatrialfibrillationananalysisfromthestartregistry
AT antonucciemilia thrombocytopeniaandmortalityriskinpatientswithatrialfibrillationananalysisfromthestartregistry
AT violifrancesco thrombocytopeniaandmortalityriskinpatientswithatrialfibrillationananalysisfromthestartregistry
AT palaretigualtiero thrombocytopeniaandmortalityriskinpatientswithatrialfibrillationananalysisfromthestartregistry
AT pignatellipasquale thrombocytopeniaandmortalityriskinpatientswithatrialfibrillationananalysisfromthestartregistry
AT thrombocytopeniaandmortalityriskinpatientswithatrialfibrillationananalysisfromthestartregistry